These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36864544)

  • 21. Variation in Medicaid and commercial coverage of cell and gene therapies.
    Beinfeld MT; Rucker JA; Jenkins NB; de Breed LA; Chambers JD
    Health Policy Open; 2023 Dec; 5():100103. PubMed ID: 38023441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing health plan evidence review practices.
    Panzer AD; Enright DE; Graff J; Chambers JD
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1053-1058. PubMed ID: 36001106
    [No Abstract]   [Full Text] [Related]  

  • 24. Balancing Evidence and Need: Variation in US Commercial Payer Coverage of Esketamine.
    Ochigbo EB; Beinfeld MT; Chambers JD
    Clin Ther; 2024 Jul; ():. PubMed ID: 39039006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
    Monge AN; Sigelman DW; Temple RJ; Chahal HS
    JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
    Kesselheim AS; Wang B; Franklin JM; Darrow JJ
    BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health plans' coverage determinations for technology-based interventions: the case of electrical bone growth stimulation.
    Huang AJ; Gemperli MP; Bergthold L; Singer SS; Garber A
    Am J Manag Care; 2004 Dec; 10(12):957-62. PubMed ID: 15617371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health Plans.
    Lenahan KL; Nichols DE; Gertler RM; Chambers JD
    Health Aff (Millwood); 2021 Nov; 40(11):1749-1757. PubMed ID: 34724434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?
    Panzer AD; Margaretos NM; Lai RC; Enright DE; Chambers JD
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1307-1311. PubMed ID: 32212282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
    Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
    JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
    Yu T; Jin S; Li C; Chambers JD; Hlávka JP
    BioDrugs; 2023 Jul; 37(4):531-540. PubMed ID: 37004706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021.
    Gupta R; Morten CJ; Zhu AY; Ramachandran R; Shah ND; Ross JS
    JAMA Health Forum; 2022 May; 3(5):e221096. PubMed ID: 35977259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease.
    Lin PJ; Levine A; Rucker J; Chambers JD
    Alzheimers Dement; 2023 Aug; 19(8):3654-3669. PubMed ID: 36852834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of orphan drug coverage restrictions in Medicare Part D.
    Yehia F; Segal JB; Anderson GF
    Am J Manag Care; 2020 Sep; 26(9):e289-e294. PubMed ID: 32930558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.
    Toyserkani GA; Huynh L; Morrato EH
    Front Public Health; 2020; 8():43. PubMed ID: 32158741
    [No Abstract]   [Full Text] [Related]  

  • 36. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited role of patient input in specialty drug coverage policies.
    D'Cruz B; Graff JS; Panzer AD; Chambers JD
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1067-1076. PubMed ID: 34337996
    [No Abstract]   [Full Text] [Related]  

  • 38. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.
    Wang S; Yang Q; Deng L; Lei Q; Yang Y; Ma P; Men Y; Yung BC; Lee RJ; Zhang M; Li N
    Drug Discov Today; 2022 May; 27(5):1236-1250. PubMed ID: 34971818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
    Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
    Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.